Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
dyne therapeutics
myotonic dystrophy type 1
national top stories
rare disease drugs
san diego blog main
ally bridge group
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
biotech ipos
blackrock
bluebird bio
casdin capital
diabetic nephropathy
duchenne muscular dystrophy
eventide asset management
facioscapulohumeral muscular dystrophy
fda
focal segmental glomerulosclerosis
gene therapy
goldfinch bio
irving investors
jay ghosh
joshua brumm
kaleido biosciences
metacrine
muscular dystrophy
new york blog main
nonalcoholic steatohepatitis
rare diseases
romesh subramanian
What
drug
genetic
3
×
ipo
3
×
medicines
company
diseases
dyne
million
muscle
raised
rare
therapeutics
ago
analysis
bio
biotech
biotechs
bring
brings
considering
data
develop
developing
disorders
dyne’s
early
employing
expected
experimental
eyes
goldfinch
having
humans
ipos
kidney
later
lead
long
muscular
new
Language
unset
Current search:
ipo
×
genetic
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later